Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4248 | Vitamin B12 Wiki | 0.41 |
| drug1364 | Electrotherapy group Wiki | 0.41 |
| drug654 | Brief educational video Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3000 | Plant Polyphenol Wiki | 0.41 |
| drug1750 | Home-based exercise Wiki | 0.41 |
| drug1559 | Flywheel exercise Wiki | 0.41 |
| drug1171 | Ddrops® products, 50,000 IU, Oral Wiki | 0.41 |
| drug1266 | Doxycycline Hcl Wiki | 0.41 |
| drug4337 | Zinc Citrate Wiki | 0.41 |
| drug1746 | Home exercise Wiki | 0.29 |
| drug4249 | Vitamin C Wiki | 0.22 |
| drug4335 | Zinc Wiki | 0.14 |
| drug2029 | Ivermectin Wiki | 0.09 |
| drug421 | Azithromycin Wiki | 0.07 |
| drug1775 | Hydroxychloroquine Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D051346 | Mobility Limitation NIH | 0.18 |
| D020370 | Osteoarthritis, Knee NIH | 0.18 |
| D010003 | Osteoarthritis, NIH | 0.17 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014808 | Vitamin D Deficiency NIH | 0.14 |
| D059350 | Chronic Pain NIH | 0.11 |
| D018450 | Disease Progression NIH | 0.09 |
| D016638 | Critical Illness NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005086 | Knee osteoarthritis HPO | 0.18 |
| HP:0002355 | Difficulty walking HPO | 0.18 |
| HP:0002758 | Osteoarthritis HPO | 0.17 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100512 | Low levels of vitamin D HPO | 0.14 |
| HP:0012532 | Chronic pain HPO | 0.11 |
Navigate: Correlations HPO
There are 6 clinical trials
A novel coronavirus disease 2019 (COVID-19) outbreak is a global dramatic pandemic that is immeasurably impacting the communities. Due to lack of data, symptomatic management is used for COVID-19 infection including oxygen therapy and mechanical ventilation for those with severe infection. Considering immunomodulatory, anti-inflammatory anti-fibrotic and anti-oxidant actions of vitamin D, it's safety and ease of administration, as well as direct effects of vitamin D on immune cell proliferation and activity, pulmonary ACE2 expression and reducing surface tension, evaluation of vitamin D supplementation as an adjuvant therapeutic intervention could be of substantial clinical and economic significance. High prevalence of vitamin D deficiency in elderly, smokers, patients with chronic diseases and excess uptake by adipose tissue in obesity make investigations of its role as a secondary therapeutic agent in COVID-19 conceivable. It should be necessary to monitor serum 25(OH)D levels in all inpatient and outpatient populations with COVID-19 to identify the importance of maintaining or promptly increasing circulating levels of 25(OH)D into the optimal range of 100-150 nmol/L. The aim of this study is to conduct a double blind, randomized, controlled three weeks clinical trial on the efficacy of vitamin D (daily low dose versus weekly high dose) in COVID-19 patients in order to determine the relationship between baseline vitamin D deficiency and clinical characteristics and to asses patients' response to vitamin D supplementation in week three and determine its association with disease progression and recovery. Subjects who are randomized to high-dose will be asked to take 50,000 IU for two times during the first week and one dose over second and third weeks to quickly raise their serum levels. Subjects in the low-dose arm will take vitamin D 1000 IU daily for three weeks.
Description: Number of Participants whose symptoms recovered over three weeks
Measure: Symptoms recovery Time: Time from onset of intervention to day 21Description: Number of patients who required hospitalization
Measure: Hospitalization Time: Between diagnosis and day 21Description: x 109/L
Measure: Blood white blood cell count (WBC) Time: At day 0 before starting intervention and day 21 of interventionDescription: If patients required mechanical ventilation at any time after diagnosis
Measure: Duration of mechanical ventilation Time: Between diagnosis and day 21Description: Length of stay in hospital (days)
Measure: Duration of hospitalization Time: Between diagnosis and day 21Description: Number of patients who required ICU
Measure: Intensive care unit (ICU) admission Time: Between diagnosis and day 21Description: Length of stay in ICU
Measure: Duration of ICU stay Time: Between diagnosis and day 21Description: mg/L
Measure: Blood C-reactive protein (CRP) Time: Baseline and day 21Description: number of lymphocytes in 1 microliter (µL) of blood
Measure: Blood Lymphocyte count Time: Baseline and day 21Description: ng/mL
Measure: Blood Ferritin Time: Baseline and day 21Description: platelets per microliter of blood
Measure: Blood platelet count Time: Baseline and day 21Description: pg/mL
Measure: Blood interleukin-6 (IL-6) Time: Baseline and day 21Description: pg/ml
Measure: Blood Tumor Necrosis Factor alpha (TNF) Time: Baseline and day 21COVID-19 is a global pandemic. So far encouraging results have been shown in different parts of the world with the utilisation of hydroxycloroquine, zinc, and azithromycin, and early studies into some of these, plus some with Vitamin C, have also proven beneficial. Vitamin D levels have also been shown to be an important indicator to the severity of symptoms in COVID-19 patients.
Description: Composite measure: Change in severity and duration of symptoms
Measure: Symptoms Time: once daily for 15 days since enrollment/baseline at admission to hospitalDescription: total number of days in hospital since admission
Measure: Length of hospital stay Time: at 15 and 45 days since admission/ enrolmentDescription: need for invasive mechanical ventilation or mortality within 15 days from enrolment
Measure: invasive mechanical ventilation or mortality Time: any time within 15 days from enrolmentDescription: Death
Measure: Mortality Time: 15 and 45 days since enrolmentDescription: need for and number of days of invasive mechanical ventilation, in case of no need for mechanical ventilation: days=0
Measure: mechanical ventilation Time: at 15 and 45 days since enrolmentDescription: need for and number of days for humidified high-flow oxygen
Measure: oxygen Time: 15 and 45 days since enrolmentDescription: admission to ICU (intensive care unit)
Measure: ICU Time: 15 and 45 days since enrolmentDescription: days in hospital
Measure: days in hospital Time: 15 and 45 days since enrolmentDescription: days in ICU
Measure: days in ICU Time: 15 and 45 days since enrolmentDescription: need for and days of renal replacement therapy
Measure: renal replacement therapy Time: 15 and 45 days since enrolmentDescription: need for and days of Extracorporeal support
Measure: Extracorporeal support Time: 15 and 45 days since enrolmentThere is evidence that a specific plant polyphenol (a commercially available supplement) might help fight coronavirus as well as help protect the body from the effects of disease (COVID-19) caused by the infection. In this proof-of-concept pilot study we will compare the effects of a specific plant polyphenol to placebo to assess the safety of the polyphenol and explore effectiveness.
Description: Proportion of study participants admitted to the hospital within 21 days of randomization
Measure: Hospitalization rates for COVID-19 Time: 21 days from study randomizationDescription: Proportion of study participants admitted within 21 who subsequently get admitted to the ICU
Measure: ICU Admission Rates Time: 21 days from randomizationDescription: Proportion of study participants who get admitted with 21 day of randomization who receiving invasive ventilation.
Measure: Invasive Ventilation Rates Time: 21 days from randomizationDescription: Diarrhea, nausea, abdominal cramping
Measure: Adverse events Time: 60 days from randomizationThis study will measure vitamin D levels in adults with COVID 19. Participants with low levels of vitamin D will be entered into an open label trial of supplementation with vitamin D.
Description: change in level of Vitamin D, 25-Hydroxy between the two time points
Measure: Vitamin D levels Time: baseline and after two weeks of vitamin D supplementationDescription: We will calculate the change in severity of COVID 19 symptoms from baseline to 2 weeks after vitamin D supplementation
Measure: severity of COVID 19 symptoms Time: baseline and at 2 weeks after vitamin D supplementationThe effect of Weekly 50,000 IU vitamin D3 supplements on the serum levels of selected cytokines involved in cytokine storm of Covid-19; A randomized clinical trial in the Covid-19 uninfected people with vitamin D deficiency.
Description: seum levels
Measure: IL-1 beta Time: 8 weeksDescription: serum levels
Measure: IL-6 Time: 8 weeksDescription: serum levels
Measure: TNF Time: 8 weeksDescription: ng/ml
Measure: serum concentrations of 25-hydroxyvitamin D Time: 8 weeksDescription: seum levels
Measure: lipid profile parameters Time: 8 weeksIn this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
Description: Time to negative RT-PRC result indicating that patient is no longer infective
Measure: Time to Non-Infectivity by RT-PCR Time: 6 monthsDescription: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.
Measure: Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score) Time: 6 monthsDescription: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.
Measure: Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score) Time: 6 monthsDescription: Patients will have serum stored for titer testing to compare antibody levels over time
Measure: Efficacy of Treatment as measured by Titer Time: 6 monthsDescription: Number of patients testing negative for SARS-CoV-2 by RT-PCR after 10 days of treatment
Measure: Efficacy of Treatment as measured by RT-PCR Time: 10 daysDescription: Blood D-Dimer levels
Measure: Safety of Treatment as Measured by D-Dimer Time: 6 MonthsDescription: Blood Pro-Calcitonin levels
Measure: Safety of Treatment as Measured by Pro-Calcitonin Time: 6 MonthsDescription: Blood CRP levels
Measure: Safety of Treatment as Measured by C-Reactive Protein Time: 6 MonthsDescription: Blood ferritin levels
Measure: Safety of Treatment as Measured by Ferritin Time: 6 MonthsDescription: Blood enzyme levels
Measure: Safety of Treatment as Measured by Liver Enzymes Time: 6 MonthsDescription: CBC
Measure: Safety of Treatment as Measured by Complete Blood Count Time: 6 MonthsDescription: Blood electrolytes
Measure: Safety of Treatment as Measured by Electrolyte Levels Time: 6 MonthsDescription: Presence or absence of Grade 3 or high treatment related adverse events
Measure: Safety of Treatment as Measured by Treatment Related Adverse Events Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports